Alector Company
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Investors
Founded Date:
2013-01-01
Total Funding:
194500000
Employee Number:
101-250
Funding Status:
IPO
Number Of Exists:
101-250
Last Funding Type:
Series E
Investors Number:
20
Last Funding Date:
2018-07-25
Industry:
Neurodegeneration and aging
Headquarters:
San Francisco, California, United States
Estimated Revenue:
$10M to $50M